Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy

Hybrids composed of various materials are highly versatile for drug delivery in tumor therapy including hepatocellular carcinoma. Herein, a sorafenib (SF)-loaded biomacromolecule hyaluronic acid (HA)/lipid hybrid nanoparticles (HA/SF-cLNS) were developed for targeting drug delivery. assays determine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nanomedicine (London, England) England), 2017-04, Vol.12 (8), p.911-925
Hauptverfasser:	Zhang, Jing, Wang, Tianqi, Mu, Shengjun, Olerile, Livesey D, Yu, Xiaoyue, Zhang, Na
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids Animals Biocompatibility biomacromolecule/lipid hybrid nanoparticles Cancer therapies Carcinoma, Hepatocellular - drug therapy Cell Survival - drug effects Drug Delivery Systems Drug therapy enzyme-responsive Enzymes HCC Hep G2 Cells Humans hyaluronic acid Inhibitor drugs Kinases Lipids Lipids - administration & dosage Lipids - chemistry Liver cancer Liver Neoplasms - drug therapy Mice Nanoparticles Nanoparticles - administration & dosage Nanoparticles - chemistry Niacinamide - administration & dosage Niacinamide - analogs & derivatives Niacinamide - chemistry Pharmaceuticals Phenylurea Compounds - administration & dosage Phenylurea Compounds - chemistry Polyethylene glycol Polymers sorafenib Targeted cancer therapy Tumors Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Hybrids composed of various materials are highly versatile for drug delivery in tumor therapy including hepatocellular carcinoma. Herein, a sorafenib (SF)-loaded biomacromolecule hyaluronic acid (HA)/lipid hybrid nanoparticles (HA/SF-cLNS) were developed for targeting drug delivery. assays determined HA/SF-cLNS release behavior, enzymatic degradation, uptake and cytotoxicity. H22-bearing liver cancer xenograft murine models were used to evaluate the biodistribution and therapeutic efficacy . HA/SF-cLNS could be disassembled and drug was released in response to hyaluronidase. imaging results demonstrated HA/cLNS could enhance drug accumulation at tumor site. Meanwhile, HA/SF-cLNS exhibited improved antitumor efficacy and . HA/SF-cLNS demonstrated the potential to enhance antitumor efficacy of SF.
ISSN:	1743-5889 1748-6963
DOI:	10.2217/nnm-2016-0402